Lifecore Biomedical, Inc. De (LFCR) EBITDA (2010 - 2025)

Lifecore Biomedical has reported EBITDA for 16 years, with the latest figure at $5.3 million in Q2 2025.

• On a quarterly basis, EBITDA rose 147.88% year-over-year to $5.3 million in Q2 2025; TTM through May 2025 was -$17.2 million, a 95.01% decrease from a year earlier, with the FY2025 full-year figure at -$17.2 million, down 94.99% from the prior year.
• EBITDA was $5.3 million for Q2 2025 at Lifecore Biomedical, up from -$9.0 million in the prior quarter.
• The five-year high for EBITDA was $5.3 million in Q2 2025, with the low at -$11.6 million in Q3 2024.
• Average EBITDA over 5 years is -$3.7 million, with a median of -$3.7 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2022: EBITDA surged 168.56% in 2021, then slumped 13302.74% in 2022.
• Over 5 years, EBITDA stood at $3.7 million in 2021, then plunged by 245.04% to -$5.4 million in 2022, then jumped by 72.29% to -$1.5 million in 2023, then plunged by 32.1% to -$2.0 million in 2024, then soared by 371.92% to $5.3 million in 2025.
• The last three EBITDA figures came in at $5.3 million (Q2 2025), -$9.0 million (Q1 2025), and -$2.0 million (Q4 2024), per Business Quant data.